Abstract

The Inflammatory Bowel Disease Biomarkers Consortium (IBD-BIOM) addresses the need to improve understanding of inflammatory bowel disease (IBD) through new biomarkers into molecular dysfunctions that give rise to IBD. The targeted biomarkers will be translated into early-detection clinical diagnostic tests for IBD patients.

Mission

IBD-BIOM aims to advance the development of early warning diagnostics and molecular biomarker discovery for IBD using integrated “–omics” technologies. The aim is to discover reliable biomarkers that could allow insights into the molecular pathogenesis of IBD and development of prognostic tools and targeted therapies.

IBD-BIOM aims to discover clinical biomarkers for IBD to (a) enable the early diagnosis of patients with IBD and (b) point to possible molecular targets for new, improved therapies to alleviate the
suffering of IBD patients.

Financing

IBD-BIOM is funded by the European Union through the Seventh Framework Programme (Reference: 305676).

Homepage http://www.ibdbiom.eu/

Sponsors & Partners

Cedars Sinai Medical Center
Genos Ltd (Croatia)
IP Research Consulting SAS (France)
Leiden University Medical Center (Netherlands)
Ludger Ltd (UK)
Max Planck Institute (Berlin)
University Hospital Careggi (Florence)
University of Edinburgh
University of Zagreb (Croatia)

Updated: 04/15/2016